Breast cancer staging is essential for defining the treatment plan and is determined by considering tumour size, lymph node involvement, metastasis presence and specific biomarkers such as oestrogen receptors, progesterone receptors and the ERBB2 receptor (formerly known as HER2). This evidence concerns the gene PGR and neoplasm.